Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Rating) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Shares of NASDAQ CYCC opened at $1.99 on Tuesday. The company has a market cap of $19.89 million, a price-to-earnings ratio of -0.93 and a beta of 1.21. Cyclacel Pharmaceuticals has a 12-month low of $1.90 and a 12-month high of $7.95. The firm’s 50-day simple moving average is $3.14 and its 200 day simple moving average is $3.81.

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Rating) last announced its quarterly earnings data on Monday, March 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.17. During the same period in the prior year, the firm earned ($1.34) EPS. On average, research analysts predict that Cyclacel Pharmaceuticals will post -2.5 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in Cyclacel Pharmaceuticals by 15.9% during the 3rd quarter. Geode Capital Management LLC now owns 58,934 shares of the biotechnology company’s stock worth $310,000 after acquiring an additional 8,074 shares during the last quarter. NEXT Financial Group Inc boosted its holdings in shares of Cyclacel Pharmaceuticals by 61.7% in the 4th quarter. NEXT Financial Group Inc now owns 23,852 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 9,100 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Cyclacel Pharmaceuticals in the 4th quarter valued at approximately $39,000. Dimensional Fund Advisors LP acquired a new stake in shares of Cyclacel Pharmaceuticals in the 3rd quarter valued at approximately $74,000. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Cyclacel Pharmaceuticals by 5.3% in the 3rd quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biotechnology company’s stock valued at $2,108,000 after buying an additional 20,000 shares during the last quarter. 37.00% of the stock is owned by hedge funds and other institutional investors.

About Cyclacel Pharmaceuticals (Get Rating)

Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

Further Reading

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.